Short Interest in Hologic, Inc. (NASDAQ:HOLX) Grows By 71.7%

Hologic, Inc. (NASDAQ:HOLX) was the recipient of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 8,301,510 shares, an increase of 71.7% from the February 12th total of 4,834,145 shares. Based on an average daily trading volume, of 2,180,670 shares, the days-to-cover ratio is currently 3.8 days. Currently, 3.8% of the company’s stock are short sold. Currently, 3.8% of the company’s stock are short sold. Based on an average daily trading volume, of 2,180,670 shares, the days-to-cover ratio is currently 3.8 days.

Hedge Funds Weigh In On Hologic

Several hedge funds have recently modified their holdings of HOLX. NewEdge Wealth LLC increased its stake in Hologic by 3.8% during the third quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock worth $281,000 after acquiring an additional 138 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Hologic by 8.1% in the 4th quarter. Allworth Financial LP now owns 1,890 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 141 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Hologic by 1.9% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 7,675 shares of the medical equipment provider’s stock valued at $572,000 after purchasing an additional 142 shares during the last quarter. Capital Investment Counsel Inc increased its position in shares of Hologic by 2.6% during the 2nd quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider’s stock valued at $379,000 after purchasing an additional 150 shares during the last quarter. Finally, BCS Private Wealth Management Inc. raised its holdings in Hologic by 2.5% during the 4th quarter. BCS Private Wealth Management Inc. now owns 6,105 shares of the medical equipment provider’s stock valued at $455,000 after buying an additional 150 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on HOLX. BNP Paribas Exane downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a report on Friday, November 21st. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Finally, Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and cut their price objective for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $78.42.

Hologic Stock Performance

Shares of NASDAQ HOLX traded down $0.03 during trading on Friday, hitting $75.19. The company had a trading volume of 2,331,740 shares, compared to its average volume of 2,554,059. Hologic has a 12 month low of $51.90 and a 12 month high of $75.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The firm has a market capitalization of $16.78 billion, a P/E ratio of 31.33, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. The stock has a 50 day simple moving average of $75.12 and a 200 day simple moving average of $72.58.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.87 earnings per share. As a group, analysts anticipate that Hologic will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.